Gene therapy for blood cancer shows 73 per cent response rate in clinical trials
Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...
The Manila Times1h
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...
The Manila Times8h
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, ...
BioSpace5h
5 CAR T Cell Therapies With Autoimmune Readouts in 2025
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Novel cancer therapy works for 73 per cent Indian patients in clinical trials: Why the Lancet report is significant
The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...